Non-adjustment for multiple testing in multi-arm trials of distinct treatments: Rationale and justification

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial

(2020) Jeremy Chataway et al.   LANCET NEUROLOGY

On the need to adjust for multiplicity in confirmatory clinical trials with master protocols

(2019) N Stallard et al.   ANNALS OF ONCOLOGY

Reporting of Multi-Arm Parallel-Group Randomized Trials

(2019) Edmund Juszczak et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

P values in display items are ubiquitous and almost invariably significant: A survey of top science journals

(2018) Ioana Alina Cristea et al.   PLoS One

Why are two mistakes not worse than one? A proposal for controlling the expected number of false claims

(2016) Thomas Jaki et al.   PHARMACEUTICAL STATISTICS

Recommendations on multiple testing adjustment in multi-arm trials with a shared control group

(2016) Dena R Howard et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

How to test hypotheses if you must

(2015) Andrew P. Grieve   PHARMACEUTICAL STATISTICS

Correcting for multiple-testing in multi-arm trials: is it necessary and is it done?

(2014) James M S Wason et al.   Trials

Multi-Arm Clinical Trials of New Agents: Some Design Considerations

(2008) B. Freidlin et al.   CLINICAL CANCER RESEARCH